|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Endothelin receptor antagonists in pulmonary arterial hypertension
1 Research Center of the Montreal Heart Institute, 2 Dept of Medicine, University of Montreal, Montreal, QC, Canada, and 3 Dept of Respiratory Medicine, Hanover Medical School, Hanover, Germany.
CORRESPONDENCE: M. M. Hoeper, Dept of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany. Fax: 49 5115328536. E-mail: hoeper.marius{at}mh-hannover.de
Keywords: Endothelin, endothelin receptor antagonists, hypertension, pulmonary
Received: June 26, 2007
Accepted August 29, 2007
The endothelin (ET) system, especially ET-1 and the ETA and ETB receptors, has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH). Together with prostanoids and phosphodiesterase 5 inhibitors, ET receptor antagonists have become mainstays in the current treatment of PAH.
Three substances are currently available for the treatment of PAH. One of these substances, bosentan, blocks both ETA and ETB receptors, whereas the two other compounds, sitaxsentan and ambrisentan, are more selective blockers of the ETA receptor.
There is ongoing debate as to whether selective or nonselective ET receptor blockade is advantageous in the setting of PAH, although there is no clear evidence that receptor selectivity is relevant with regard to the clinical effects of these drugs.
For the time being, other features, such as safety profiles and the potential for pharmacokinetic interactions with other drugs used in the treatment of PAH, may be more important than selectivity or nonselectivity when selecting treatments for individual patients.
This article has been cited by other articles:
|
|
 |
|
  A. J. Peacock, R. Naeije, N. Galie, and L. Rubin End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J., July 1, 2009; 34(1): 231 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Spiekermann, K. Schenk, and M. M. Hoeper Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension Eur. Respir. J., July 1, 2009; 34(1): 276 - 276. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, H. Gall, H. J. Seyfarth, M. Halank, H. A. Ghofrani, J. Winkler, H. Golpon, K. M. Olsson, N. Nickel, C. Opitz, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Eur. Respir. J., July 1, 2009; 34(1): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, J. A. Barbera, R. N. Channick, P. M. Hassoun, I. M. Lang, A. Manes, F. J. Martinez, R. Naeije, H. Olschewski, J. Pepke-Zaba, et al. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S85 - S96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Opitz and L. J. Rubin Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur. Respir. J., June 1, 2009; 33(6): 1247 - 1249. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, K. M. Olsson, A. Schneider, and H. Golpon Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy Eur. Respir. J., June 1, 2009; 33(6): 1518 - 1519. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Faughnan, J. T. Granton, and L. H. Young The pulmonary vascular complications of hereditary haemorrhagic telangiectasia Eur. Respir. J., May 1, 2009; 33(5): 1186 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert More pressure on pulmonary hypertension Eur. Respir. Rev., March 1, 2009; 18(111): 1 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Devaraj, A. U. Wells, M. G. Meister, T. J. Corte, and D. M. Hansell The Effect of Diffuse Pulmonary Fibrosis on the Reliability of CT Signs of Pulmonary Hypertension Radiology, December 1, 2008; 249(3): 1042 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chaouat, R. Naeije, and E. Weitzenblum Pulmonary hypertension in COPD Eur. Respir. J., November 1, 2008; 32(5): 1371 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Janosi, F. Petak, F. Fontao, D. R. Morel, M. Beghetti, and W. Habre Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung Exp Physiol, November 1, 2008; 93(11): 1210 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper Treating pulmonary hypertension in COPD: where do we start? Eur. Respir. J., September 1, 2008; 32(3): 541 - 542. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper and M. Humbert A message on the lips Eur. Respir. J., July 1, 2008; 32(1): 15 - 16. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |